The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.本發明提供包含人類抗TNFα抗體或其抗原結合部分之液體水性醫藥調配物,與注射包含至少一種鹽及/或至少一種緩衝液之其他相同調配物相比,其使個體與注射有關之疼痛減少至少約50%。本發明亦提供在皮下投與個體時具有增加之生物可用性的包含人類抗TNFα抗體或其抗原結合部分之液體水性醫藥調配物。該調配物可包含治療性蛋白質,諸如人類抗TNFα抗體或其抗原結合部分,或其生物類似物(biosimilar)。